Article Information
- Received April 21, 2015
- Revision received November 2, 2015
- Accepted November 7, 2015
- First published December 16, 2015.
- Version of record published December 16, 2015.
Author Information
- Jérémy Ferrier1,2,3,
- Mathilde Bayet-Robert5,
- Romain Dalmann1,2,3,
- Abderrahim El Guerrab1,2,4,
- Youssef Aissouni2,
- Danielle Graveron-Demilly6,
- Maryse Chalus1,2,3,
- Jérémy Pinguet3,7,
- Alain Eschalier1,2,3,7,
- Damien Richard3,7,
- Laurence Daulhac1,2,3,
- Fabien Marchand1,2,3,*, and
- David Balayssac1,2,3,7,*
- 1Clermont Université, Université d'Auvergne, Pharmacologie Fondamentale et Clinique de la Douleur, F-63000 Clermont-Ferrand, France,
- 2Inserm, U1107 NEURO-DOL, F-63001 Clermont-Ferrand, France,
- 3Institut Analgesia, F-63000 Clermont-Ferrand, France,
- 4Centre Jean Perrin, ERTICA EA4677 Université d'Auvergne, F-63001, Clermont-Ferrand, France,
- 5Université Lyon, CNRS, ENS Lyon, UCB Lyon 1, Ctr RMN Très Hauts Champs, F-69100 Villeurbanne, France,
- 6Université Lyon 1, Inserm U1044, CNRS UMR 5220, Laboratory CREATIS, F-69616 Villeurbanne, France, and
- 7CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France
Author contributions
Author contributions: J.F., A.E., F.M., and D.B. designed research; J.F., M.B.-R., R.D., A.E.G., Y.A., D.G.-D., M.C., J.P., D.R., L.D., and D.B. performed research; J.F., Y.A., F.M., and D.B. analyzed data; J.F., A.E., F.M., and D.B. wrote the paper.
↵*F.M. and D.B. contributed equally to this work.
Disclosures
- Received April 21, 2015.
- Revision received November 2, 2015.
- Accepted November 7, 2015.
This work was supported by the Auvergne University, INSERM, and the local branch of the Ligue Contre le Cancer (French League Against Cancer). J.F. has received a PhD Grant from the regional council of Auvergne and the European Community. We thank the European jMRUI project (EC-HCM/ CHRX-CT94-0432, EC-TMR/ERBFMRXCT970160), FAST (FP6-MC-RTN-035801), and TRANSACT (FP7-PEOPLE-2012-ITN-316679).
The authors declare no competing financial interests.
- Correspondence should be addressed to Dr. Fabien Marchand, INSERM U1107 NEURO-DOL, 28 place Henri Dunant, BP 38, 63000 Clermont-Ferrand Cedex 01, France. fabien.marchand{at}udamail.fr
Online Impact